Sec Form 4 Filing - Margolis Jeff Eliot @ RespireRx Pharmaceuticals Inc. - 2020-09-30

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Margolis Jeff Eliot 2. Issuer Name and Ticker or Trading Symbol RespireRx Pharmaceuticals Inc. [ RSPI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner X __ Officer (give title below) _____ Other (specify below) SVP, CFO, Secret'y & Treasurer (Last) (First) (Middle) C/O RESPIRERX PHARMACEUTICALS INC., 126 VALLEY ROAD, SUITE C 3. Date of Earliest Transaction (MM/DD/YY) 09/30/2020 (Street) GLEN ROCK, NJ07452 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 09/30/2020 C( 1 ) 91,871,094 A 96,151,863 I By Trust ( 2 ) Common Stock 09/30/2020 C( 1 ) 5,017,144 A 5,142,351 I By Trust ( 3 ) Common Stock 09/30/2020 C( 1 ) 5,017,144 A 5,142,351 I By Trust ( 4 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series H Preferred Stock ( 5 ) $ 0.0064 09/30/2020 J( 6 ) 150 09/30/2020 09/30/2023 Conversion Units ( 7 ) 23,437,500 ( 6 ) 150 D Series H Preferred Stock ( 5 ) $ 0.0064 09/30/2020 G( 8 ) 136 09/30/2020 09/30/2023 Conversion Units ( 7 ) 21,250,000 $ 0 14 D Series H Preferred Stock ( 5 ) $ 0.0064 09/30/2020 G( 8 ) 136 09/30/2020 09/30/2023 Conversion Units ( 7 ) 21,250,000 $ 0 587.975 ( 9 ) I By Trust ( 10 ) Series H Preferred Stock ( 5 ) $ 0.0064 09/30/2020 G( 8 ) 7 09/30/2020 09/30/2023 Conversion Units ( 7 ) 1,093,750 $ 0 7 D Series H Preferred Stock ( 5 ) $ 0.0064 09/30/2020 G( 8 ) 7 09/30/2020 09/30/2023 Conversion Units ( 7 ) 1,093,750 $ 0 32.11 ( 11 ) I By Trust ( 12 ) Series H Preferred Stock ( 5 ) $ 0.0064 09/30/2020 G( 8 ) 7 09/30/2020 09/30/2023 Conversion Units ( 7 ) 1,093,750 $ 0 0 D Series H Preferred Stock ( 5 ) $ 0.0064 09/30/2020 G( 8 ) 7 09/30/2020 09/30/2023 Conversion Units ( 7 ) 1,093,750 $ 0 32.11 ( 13 ) I By Trust ( 14 ) Warrants (to purchase Common Stock) $ 0.007 09/30/2020 C( 1 ) 91,871,094 09/30/2020 09/30/2023 Common Stock 91,871,094 ( 1 ) 91,871,094 I By Trust ( 2 ) Warrants (to purchase Common Stock) $ 0.007 09/30/2020 C( 1 ) 5,017,144 09/30/2020 09/30/2023 Common Stock 5,017,144 ( 1 ) 5,017,144 I By Trust ( 3 ) Warrants (to purchase Common Stock) $ 0.007 09/30/2020 C( 1 ) 5,017,144 09/30/2020 09/30/2023 Common Stock 5,017,144 ( 1 ) 5,017,144 I By Trust ( 4 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Margolis Jeff Eliot C/O RESPIRERX PHARMACEUTICALS INC. 126 VALLEY ROAD, SUITE C GLEN ROCK, NJ07452 X X SVP, CFO, Secret'y & Treasurer Signatures /s/ Jeff Eliot Margolis 10/02/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On September 30, 2020, each of the trusts into which Mr. Margolis transferred shares of the Company's Series H 2% Voting, Non-Participating, Convertible Preferred Stock ("Series H Preferred") converted all of their outstanding shares of the Series H Preferred into a total of 101,905,382 Conversion Units comprising 101,905,382 shares of the common stock of the Company and 101,905,382 warrants exercisable into 101,905,382 shares of the common stock of the Company. ( 2 )These securities are held by a family trust for the benefit of Mr. Margolis's spouse. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose. ( 3 )These securities are held by a family trust for the benefit of Mr. Margolis's son. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose. ( 4 )These securities are held by a family trust for the benefit of Mr. Margolis's daughter. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose. ( 5 )The full designation of this class of preferred stock is "Series H 2% Voting, Non-Participating, Convertible Preferred Stock". ( 6 )On September 30, 2020, Mr. Margolis agreed to forgive a portion of accrued compensation owing from RespireRx Pharmaceuticals Inc. (the "Company") equal to $150,000, and in exchange, the Company issued to Mr. Margolis 150 shares of Series H Preferred stock, which equates to a per share value of $1,000.00 per share. ( 7 )Each Conversion Unit consists of one share of the common stock of the Company, and one warrant exercisable into one share of the common stock of the Company (such warrant having an initial exercise price of $0.007 per share, and terminating on September 30, 2023). ( 8 )These dispositions and acquisitions reflect estate planning transactions. These securities are being contributed to trusts for the benefit of Mr. Margolis' spouse and children, as specified. ( 9 )This reflects the 136 Series H Preferred shares transferred on September 30, 2020, plus 450 Series H Preferred shares previously transferred to the trust on July 13, 2020, plus 1.975 additional dividend shares of Series H Preferred on the 450 Series H Preferred shares held since July 13, 2020. ( 10 )Mr. Margolis gifted these securities into a family trust for the benefit of Mr. Margolis's spouse. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose. ( 11 )This reflects the 7 Series H Preferred shares transferred on September 30, 2020, plus 25 Series H Preferred shares previously transferred to the trust on July 13, 2020, plus 0.1097222 additional dividend shares of Series H Preferred on the 25 Series H Preferred shares held since July 13, 2020. ( 12 )Mr. Margolis gifted these securities into a family trust for the benefit of his son. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose. ( 13 )This reflects the 7 Series H Preferred shares transferred on September 30, 2020, plus 25 Series H Preferred shares previously transferred to the trust on July 13, 2020, plus 0.1097222 additional dividend shares of Series H Preferred on the 25 Series H Preferred shares held since July 13, 2020. ( 14 )Mr. Margolis gifted these securities into a family trust for the benefit of his daughter. Mr. Margolis's spouse is a trustee of the trust. Mr. Margolis disclaims beneficial ownership of these securities, and the filing of this report is not an admission that Mr. Margolis is the beneficial owner of these securities for purposes of Section 16 or any other purpose.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.